S&P 500   3,240.24 (-2.39%)
DOW   26,841.48 (-2.95%)
QQQ   263.07 (-1.42%)
AAPL   106.87 (+0.03%)
MSFT   198.90 (-0.74%)
FB   246.14 (-2.53%)
GOOGL   1,417.13 (-2.34%)
AMZN   2,886.75 (-2.31%)
NVDA   490.51 (+0.60%)
TSLA   439.68 (-0.56%)
BABA   270.47 (-0.71%)
CGC   15.55 (-4.95%)
GE   6.24 (-9.30%)
MU   48.70 (-4.02%)
AMD   76.39 (+1.95%)
T   28.27 (-2.28%)
F   6.85 (-5.26%)
ACB   6.31 (-3.37%)
GILD   63.54 (-2.32%)
NFLX   478.13 (+1.74%)
DIS   123.92 (-3.66%)
BAC   24.06 (-4.56%)
BA   156.15 (-3.10%)
S&P 500   3,240.24 (-2.39%)
DOW   26,841.48 (-2.95%)
QQQ   263.07 (-1.42%)
AAPL   106.87 (+0.03%)
MSFT   198.90 (-0.74%)
FB   246.14 (-2.53%)
GOOGL   1,417.13 (-2.34%)
AMZN   2,886.75 (-2.31%)
NVDA   490.51 (+0.60%)
TSLA   439.68 (-0.56%)
BABA   270.47 (-0.71%)
CGC   15.55 (-4.95%)
GE   6.24 (-9.30%)
MU   48.70 (-4.02%)
AMD   76.39 (+1.95%)
T   28.27 (-2.28%)
F   6.85 (-5.26%)
ACB   6.31 (-3.37%)
GILD   63.54 (-2.32%)
NFLX   478.13 (+1.74%)
DIS   123.92 (-3.66%)
BAC   24.06 (-4.56%)
BA   156.15 (-3.10%)
S&P 500   3,240.24 (-2.39%)
DOW   26,841.48 (-2.95%)
QQQ   263.07 (-1.42%)
AAPL   106.87 (+0.03%)
MSFT   198.90 (-0.74%)
FB   246.14 (-2.53%)
GOOGL   1,417.13 (-2.34%)
AMZN   2,886.75 (-2.31%)
NVDA   490.51 (+0.60%)
TSLA   439.68 (-0.56%)
BABA   270.47 (-0.71%)
CGC   15.55 (-4.95%)
GE   6.24 (-9.30%)
MU   48.70 (-4.02%)
AMD   76.39 (+1.95%)
T   28.27 (-2.28%)
F   6.85 (-5.26%)
ACB   6.31 (-3.37%)
GILD   63.54 (-2.32%)
NFLX   478.13 (+1.74%)
DIS   123.92 (-3.66%)
BAC   24.06 (-4.56%)
BA   156.15 (-3.10%)
S&P 500   3,240.24 (-2.39%)
DOW   26,841.48 (-2.95%)
QQQ   263.07 (-1.42%)
AAPL   106.87 (+0.03%)
MSFT   198.90 (-0.74%)
FB   246.14 (-2.53%)
GOOGL   1,417.13 (-2.34%)
AMZN   2,886.75 (-2.31%)
NVDA   490.51 (+0.60%)
TSLA   439.68 (-0.56%)
BABA   270.47 (-0.71%)
CGC   15.55 (-4.95%)
GE   6.24 (-9.30%)
MU   48.70 (-4.02%)
AMD   76.39 (+1.95%)
T   28.27 (-2.28%)
F   6.85 (-5.26%)
ACB   6.31 (-3.37%)
GILD   63.54 (-2.32%)
NFLX   478.13 (+1.74%)
DIS   123.92 (-3.66%)
BAC   24.06 (-4.56%)
BA   156.15 (-3.10%)
Log in
NASDAQ:NVAX

Novavax Stock Forecast, Price & News

$109.87
+1.51 (+1.39 %)
(As of 09/21/2020 02:35 PM ET)
Add
Compare
Today's Range
$101.80
Now: $109.87▼
$110.45
50-Day Range
$85.31
MA: $127.28▼
$178.51
52-Week Range
$3.54
Now: $109.87▼
$189.40
Volume60,507 shs
Average Volume8.55 million shs
Market Capitalization$6.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.51
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Read More
Novavax logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.87 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NVAX
Previous Symbol
CUSIP67000210
CIK1000694
Webwww.novavax.com
Phone240-268-2000

Debt

Debt-to-Equity Ratio1.74
Current Ratio2.98
Quick Ratio2.98

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio15.07
P/E GrowthN/A

Sales & Book Value

Annual Sales$18.66 million
Price / Sales360.80
Cash FlowN/A
Price / Cash FlowN/A
Book Value($5.75) per share
Price / Book-19.11

Profitability

EPS (Most Recent Fiscal Year)($5.80)
Net Income$-132,690,000.00
Net Margins-185.63%
Return on EquityN/A
Return on Assets-25.13%

Miscellaneous

Employees373
Outstanding Shares61,278,000
Market Cap$6.73 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$109.87
+1.51 (+1.39 %)
(As of 09/21/2020 02:35 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novavax (NASDAQ:NVAX) Frequently Asked Questions

How has Novavax's stock been impacted by COVID-19 (Coronavirus)?

Novavax's stock was trading at $10.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVAX shares have increased by 944.4% and is now trading at $109.77.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Novavax?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Novavax.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Novavax.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the Zacks' consensus estimate of ($0.60) by $0.30. The biopharmaceutical company earned $35.50 million during the quarter, compared to analysts' expectations of $5.67 million. The firm's revenue for the quarter was up 944.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.69) EPS.
View Novavax's earnings history.

When did Novavax's stock split? How did Novavax's stock split work?

Novavax's stock reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

7 Wall Street analysts have issued 12 month price targets for Novavax's shares. Their forecasts range from $15.00 to $275.00. On average, they expect Novavax's stock price to reach $138.64 in the next twelve months. This suggests a possible upside of 26.3% from the stock's current price.
View analysts' price targets for Novavax.

Who are some of Novavax's key competitors?

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX) and Repligen (RGEN).
View all competitors.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Egalet (EGLT), Advanced Micro Devices (AMD), EXACT Sciences (EXAS) and Pfizer (PFE).

Who are Novavax's key executives?

Novavax's management team includes the following people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
  • Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
  • Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 65)
  • Ms. Erika S. Trahan, Sr. Mang. of Investor & PR

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.57%), Nuveen Asset Management LLC (0.79%), Charles Schwab Investment Management Inc. (0.65%), Perceptive Advisors LLC (0.57%), Hillhouse Capital Advisors LTD. (0.53%) and Bank of New York Mellon Corp (0.51%). Company insiders that own Novavax stock include Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Rachel K King.
View institutional ownership trends for Novavax.

Which institutional investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Goldman Sachs Group Inc., Beirne Wealth Consulting Services LLC, UBS Group AG, Advisor Group Holdings Inc., Leap Investments LP, Commonwealth Equity Services LLC, and Sargent Investment Group LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino, and Michael A Mcmanus Jr.
View insider buying and selling activity for Novavax.

Which institutional investors are buying Novavax stock?

NVAX stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Perceptive Advisors LLC, Hillhouse Capital Advisors LTD., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Man Group plc, Charles Schwab Investment Management Inc., and Swiss National Bank. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $109.77.

How big of a company is Novavax?

Novavax has a market capitalization of $6.73 billion and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.